Boxer Capital Management
Latest statistics and disclosures from Boxer Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are TNGX, QURE, RVMD, KYMR, KOD, and represent 56.67% of Boxer Capital Management's stock portfolio.
- Added to shares of these 10 stocks: PTCT (+$12M), CYTK (+$11M), ABVX (+$10M), INO (+$5.4M), CELC, SRPT, SLDB, DNLI, PTGX, PGEN.
- Started 15 new stock positions in APGE, MIST, PEPG, INO, CYTK, Lb Pharmaceuticals, CELC, PGEN, AVTX, MNMD. DNLI, SLDB, PTCT, ABVX, MLTX.
- Reduced shares in these 10 stocks: MRUS (-$23M), RVMD (-$18M), Iteos Therapeutics (-$8.2M), KYMR (-$6.4M), QURE (-$5.8M), REPL, AMLX, KALV, CDTX, TIL.
- Sold out of its position in Iteos Therapeutics.
- Boxer Capital Management was a net seller of stock by $-907k.
- Boxer Capital Management has $314M in assets under management (AUM), dropping by 57.92%.
- Central Index Key (CIK): 0002018299
Tip: Access up to 7 years of quarterly data
Positions held by Boxer Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Boxer Capital Management
Boxer Capital Management holds 34 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Tango Therapeutics (TNGX) | 26.2 | $82M | 9.8M | 8.40 |
|
|
| Uniqure Nv SHS (QURE) | 14.9 | $47M | -11% | 800k | 58.37 |
|
| Revolution Medicines (RVMD) | 6.0 | $19M | -49% | 400k | 46.70 |
|
| Kymera Therapeutics (KYMR) | 5.8 | $18M | -26% | 319k | 56.60 |
|
| Kodiak Sciences (KOD) | 3.9 | $12M | 750k | 16.37 |
|
|
| Ptc Therapeutics I (PTCT) | 3.9 | $12M | NEW | 200k | 61.37 |
|
| Amylyx Pharmaceuticals (AMLX) | 3.9 | $12M | -26% | 900k | 13.59 |
|
| Urogen Pharma (URGN) | 3.7 | $12M | 575k | 19.95 |
|
|
| Merus N V (MRUS) | 3.6 | $11M | -67% | 120k | 94.15 |
|
| Cytokinetics Com New (CYTK) | 3.5 | $11M | NEW | 200k | 54.96 |
|
| Abivax Sa Sponsored Ads (ABVX) | 3.2 | $10M | NEW | 120k | 84.90 |
|
| Protagonist Therapeutics (PTGX) | 2.3 | $7.3M | +83% | 110k | 66.43 |
|
| Nektar Therapeutics Com New (NKTR) | 2.3 | $7.1M | 125k | 56.90 |
|
|
| Crescent Biopharma (CBIO) | 1.7 | $5.4M | 454k | 11.89 |
|
|
| Inovio Pharmaceuticals Com Shs (INO) | 1.7 | $5.4M | NEW | 2.3M | 2.34 |
|
| Sarepta Therapeutics (SRPT) | 1.5 | $4.8M | +900% | 250k | 19.27 |
|
| Cidara Therapeutics Com New (CDTX) | 1.5 | $4.6M | -12% | 48k | 95.76 |
|
| Celcuity (CELC) | 1.4 | $4.4M | NEW | 90k | 49.40 |
|
| Replimune Group (REPL) | 1.4 | $4.4M | -52% | 1.1M | 4.19 |
|
| Solid Biosciences Com New (SLDB) | 1.2 | $3.7M | NEW | 600k | 6.17 |
|
| Denali Therapeutics (DNLI) | 1.2 | $3.6M | NEW | 250k | 14.52 |
|
| Precigen (PGEN) | 0.9 | $2.8M | NEW | 850k | 3.29 |
|
| Apogee Therapeutics (APGE) | 0.6 | $2.0M | NEW | 50k | 39.73 |
|
| Mind Medicine Mindmed Com New (MNMD) | 0.6 | $1.9M | NEW | 164k | 11.79 |
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 0.6 | $1.8M | NEW | 250k | 7.17 |
|
| Nurix Therapeutics (NRIX) | 0.5 | $1.6M | 175k | 9.24 |
|
|
| Avalo Therapeutics Com New (AVTX) | 0.5 | $1.6M | NEW | 125k | 12.71 |
|
| Milestone Pharmaceuticals (MIST) | 0.4 | $1.3M | NEW | 667k | 2.00 |
|
| Pepgen (PEPG) | 0.4 | $1.2M | NEW | 250k | 4.62 |
|
| Lb Pharmaceuticals Com Shs | 0.4 | $1.1M | NEW | 70k | 15.79 |
|
| Instil Bio Com New (TIL) | 0.3 | $1.1M | -14% | 61k | 17.86 |
|
| Kalvista Pharmaceuticals (KALV) | 0.1 | $249k | -78% | 20k | 12.18 |
|
| Nuvation Bio *w Exp 02/10/202 (NUVB.WS) | 0.0 | $54k | 267k | 0.20 |
|
|
| Surrozen *w Exp 08/01/203 (SRZNW) | 0.0 | $999.990000 | 67k | 0.01 |
|
Past Filings by Boxer Capital Management
SEC 13F filings are viewable for Boxer Capital Management going back to 2024
- Boxer Capital Management 2025 Q3 filed Nov. 14, 2025
- Boxer Capital Management 2025 Q2 filed Aug. 14, 2025
- Boxer Capital Management 2025 Q1 filed May 15, 2025
- Boxer Capital Management 2024 Q4 filed Feb. 14, 2025